Effect of Rapid Transfusion With Fluid Management System (FMS) on Plasma Potassium in Liver Transplantation Recipients
Rapid infusion of red blood cells is known to result in hyperkalemia in the body. However, potassium concentration in the blood mixture (usually made of RBC, FFP and normal saline) in the reservoir of rapid infusion system and its effect on the plasma potassium change during rapid transfusion are unknown. This study is designed to investigate these changes while massive transfusion is performed during liver transplantation surgery.
Condition Requiring Rapid Transfusion During Liver Transplantation Surgery
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Potassium Change in the Fluid Management System (FMS) Reservoir and Its Effect on the Plasma Potassium Concentration During Liver Transplantation Surgery|
- potassium concentration in the Fluid Management System (FMS) reservoir [ Time Frame: after transfusion of 150 ml of blood mixture ] [ Designated as safety issue: No ]During bolus transfusion (300ml) of blood mixture, blood sample is taken from the side port of infusion line of Fluid Management System (FMS) when 150 ml of blood mixture was transfused. Because the priming volume of the internal circuit is approximately 100 ml, blood sample that was taken after 150 ml transfusion represents the content in the reservoir.
- plasma potassium of the patient [ Time Frame: before and after transfuison of 300 ml of blood mixture ] [ Designated as safety issue: No ]Just before transfusion starts, blood samples are taken from the central venous catheter and arterial line at the same time to measure baseline values. At the immediate end of transfusion, blood samples are taken again from the same sites to measure the resultant changes.
|Study Start Date:||October 2011|
|Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
plasma potassium concentrations in the Fluid Management System (FMS) reservoir, arterial blood, and central venous blood
Please refer to this study by its ClinicalTrials.gov identifier: NCT01331889
|Contact: Chul-Woo Jung, MD. PhDemail@example.com|
|Contact: Ho-Geol Ryu, MD. PhDfirstname.lastname@example.org|
|Korea, Republic of|
|Seoul National University Hospital||Recruiting|
|Seoul, Korea, Republic of|
|Contact: Chul-Woo Jung, MD. PhD 82-2-2072-2467 email@example.com|
|Sub-Investigator: Ho-Geol Ryu, MD. PhD|
|Sub-Investigator: Jiwon Lee, MD|
|Principal Investigator:||Chul-Woo Jung, MD. PhD||Seoul National University Hospital|